Evidence map›Paper›PMID 35519003›Full record

ArticleHemaSphere2022

The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA.

Miriam Rehberger, Jonas A Schäfer, Anna-Maria Krampitz, Anne Catherine Bretz, Lukas Jost, Torsten Haferlach, Thorsten Stiewe, Andreas Neubauer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Miriam RehbergerDepartment of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Gießen and Marburg and Carreras Leukemia Center, Marburg, Germany.
Jonas A SchäferDepartment of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Gießen and Marburg and Carreras Leukemia Center, Marburg, Germany.
Anna-Maria KrampitzInstitute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps University Marburg, Germany.
Anne Catherine BretzInstitute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps University Marburg, Germany.
Lukas JostInstitute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps University Marburg, Germany.
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Thorsten StieweInstitute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps University Marburg, Germany.
Andreas NeubauerDepartment of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Gießen and Marburg and Carreras Leukemia Center, Marburg, Germany.
German Center for Lung Research · DEUniversitätsklinikum Gießen und Marburg · DEMunich Leukemia Laboratory (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to cytarabine is a key problem in the treatment of acute myeloid leukemia (AML). To understand the molecular biology of resistance to cytarabine, a viability-based chemosensitizer screen was utilized. We screened synthetic lethal targets using 437 different small interfering RNAs (siRNAs) directed against factors involved in DNA repair mechanisms and cytarabine as the chemical compound. Three hits were identified:

Identifiers

PMID35519003
PMCPMC9067361
OpenAlexW4224690724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.